EA201170873A1 - Безопасное введение десмопрессина - Google Patents

Безопасное введение десмопрессина

Info

Publication number
EA201170873A1
EA201170873A1 EA201170873A EA201170873A EA201170873A1 EA 201170873 A1 EA201170873 A1 EA 201170873A1 EA 201170873 A EA201170873 A EA 201170873A EA 201170873 A EA201170873 A EA 201170873A EA 201170873 A1 EA201170873 A1 EA 201170873A1
Authority
EA
Eurasian Patent Office
Prior art keywords
desmopressin
treatment
desmopressina
safe
diuresis
Prior art date
Application number
EA201170873A
Other languages
English (en)
Other versions
EA028531B1 (ru
Inventor
Сеймор Файн
Original Assignee
Эллерген, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42168193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170873(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эллерген, Инк. filed Critical Эллерген, Инк.
Publication of EA201170873A1 publication Critical patent/EA201170873A1/ru
Publication of EA028531B1 publication Critical patent/EA028531B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A61M15/085—Fixing means therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Описано семейство интраназальных спреев-дозаторов для введения одинаковых низких доз десмопрессина для достижения безопасного диуреза у пациентов-людей. Дозаторы по изобретению можно использовать при лечении ноктурии, первичного ночного диуреза, недержания, частого мочеиспускания, несахарного диабета или любого заболевания или синдрома, при котором полезно лечение десмопрессином или при котором безопасное временное подавление выработки мочи может привести к благоприятным воздействиям на здоровье или к повышенному удобству при контроле мочеиспускания.
EA201170873A 2008-12-22 2009-12-21 Безопасный способ введения десмопрессина EA028531B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13987108P 2008-12-22 2008-12-22
PCT/US2009/068962 WO2010075266A2 (en) 2008-12-22 2009-12-21 Safe desmopressin administration

Publications (2)

Publication Number Publication Date
EA201170873A1 true EA201170873A1 (ru) 2012-02-28
EA028531B1 EA028531B1 (ru) 2017-11-30

Family

ID=42168193

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791732A EA201791732A1 (ru) 2008-12-22 2009-12-21 Безопасное введение десмопрессина
EA201170873A EA028531B1 (ru) 2008-12-22 2009-12-21 Безопасный способ введения десмопрессина

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201791732A EA201791732A1 (ru) 2008-12-22 2009-12-21 Безопасное введение десмопрессина

Country Status (19)

Country Link
US (3) US20120015880A1 (ru)
EP (2) EP2381923B2 (ru)
JP (4) JP5731396B2 (ru)
KR (2) KR101755042B1 (ru)
CN (2) CN105963834A (ru)
AU (1) AU2009330203B2 (ru)
BR (1) BRPI0923557A2 (ru)
CA (1) CA2747998C (ru)
DK (1) DK2381923T4 (ru)
EA (2) EA201791732A1 (ru)
ES (1) ES2692345T5 (ru)
IL (1) IL213699A (ru)
MX (1) MX2011006765A (ru)
NZ (1) NZ593613A (ru)
PL (1) PL2381923T3 (ru)
PT (1) PT2381923T (ru)
SG (2) SG172344A1 (ru)
WO (1) WO2010075266A2 (ru)
ZA (1) ZA201105420B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021007A1 (en) * 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
CN105963834A (zh) * 2008-12-22 2016-09-28 阿勒根公司 鼻内去氨加压素给药
PT2442821T (pt) * 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina
DK3024474T3 (da) 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
US9925232B2 (en) * 2013-07-23 2018-03-27 Serenity Pharmaceuticals, Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
CN106999538A (zh) 2014-11-20 2017-08-01 阿勒根公司 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS171787B1 (ru) 1973-11-09 1976-11-29
US4148787A (en) 1976-05-24 1979-04-10 Ferring Ab Antidiuretically effective polypeptide and a process for preparing the same
US4771769A (en) 1982-12-20 1988-09-20 Schering Corporation Hand held metered spray dispenser
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5112804A (en) 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US4944429A (en) 1987-08-28 1990-07-31 Schering Corporation Manually-operable spray dispenser with locking mechanism
US5154122A (en) 1989-10-20 1992-10-13 Sol Goldschmidt Shipping device for suspended piece goods
CN1060980A (zh) * 1990-10-26 1992-05-13 蔡东林 多用电控自控微型喷雾器
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
CA2166312C (en) * 1993-06-29 2002-04-23 Alan Harris Compositions for nasal administration of desmopressin
JPH11500646A (ja) * 1995-06-07 1999-01-19 オニール，アレクサンダー・ジョージ・ブライアン 患者により制御される薬剤供給装置
US5763398A (en) * 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
AU3421600A (en) 1999-02-14 2000-08-29 Ing. Erich Pfeiffer Gmbh Dispenser for flowable media
DE19938798A1 (de) 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
DE10110742A1 (de) 2001-02-28 2002-09-05 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
JP4210215B2 (ja) 2001-09-21 2009-01-14 インジ エリッヒ プファイファ ゲーエムベーハ 媒体リザーバを備えた投与装置とこれのためのポンプ装置
WO2003053400A1 (en) 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
EP1689419A4 (en) * 2003-11-10 2009-01-14 Reprise Biopharmaceutics Llc PHARMACEUTICAL COMPOSITIONS WITH LOW DOSES OF DESMOPRESSIN
ES2348303T3 (es) 2003-12-08 2010-12-02 Cpex Pharmaceuticals, Inc. Composiciones farmacauticas y procedimientos de tratamiento con insulina.
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
CN1785448A (zh) * 2005-11-11 2006-06-14 广东工业大学 医用防染式药雾吸入喷嘴
JP2009539856A (ja) * 2006-06-08 2009-11-19 シーペックス ファーマシューティカルズ インコーポレイテッド インシュリン組成物
CN105963834A (zh) * 2008-12-22 2016-09-28 阿勒根公司 鼻内去氨加压素给药
PT2442821T (pt) * 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina

Also Published As

Publication number Publication date
ES2692345T3 (es) 2018-12-03
KR20110102915A (ko) 2011-09-19
IL213699A0 (en) 2011-07-31
CN102355888A (zh) 2012-02-15
JP2012513403A (ja) 2012-06-14
KR20170081711A (ko) 2017-07-12
EP3437633A1 (en) 2019-02-06
JP5731396B2 (ja) 2015-06-10
JP6389209B2 (ja) 2018-09-12
EP2381923B1 (en) 2018-08-01
SG10201509152VA (en) 2015-12-30
IL213699A (en) 2016-05-31
CA2747998A1 (en) 2010-07-01
CA2747998C (en) 2016-05-31
US20120015880A1 (en) 2012-01-19
AU2009330203A1 (en) 2011-07-14
EP2381923A2 (en) 2011-11-02
ES2692345T5 (es) 2024-01-26
ZA201105420B (en) 2012-04-25
BRPI0923557A2 (pt) 2016-01-26
KR101755042B1 (ko) 2017-07-06
DK2381923T4 (da) 2023-09-11
AU2009330203B2 (en) 2015-09-03
WO2010075266A3 (en) 2011-01-06
PL2381923T3 (pl) 2019-04-30
US20200078542A1 (en) 2020-03-12
JP2015127350A (ja) 2015-07-09
SG172344A1 (en) 2011-07-28
DK2381923T3 (en) 2018-11-19
JP2018184407A (ja) 2018-11-22
JP5959076B2 (ja) 2016-08-02
NZ593613A (en) 2013-02-22
EA028531B1 (ru) 2017-11-30
US20220126039A1 (en) 2022-04-28
CN105963834A (zh) 2016-09-28
WO2010075266A2 (en) 2010-07-01
MX2011006765A (es) 2011-11-01
EP2381923B2 (en) 2023-06-07
EA201791732A1 (ru) 2018-03-30
JP2016196488A (ja) 2016-11-24
PT2381923T (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
MX343193B (es) Administracion segura de desmopresina.
EA201791732A1 (ru) Безопасное введение десмопрессина
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
NZ701038A (en) Treating acute decompensated heart failure with relaxin
IL217540A0 (en) Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
PH12018500023A1 (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
NZ593653A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
MX338764B (es) Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion.
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
NZ606977A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
GB2476202A (en) Novel choline cocrystal of epalrestat
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
NZ599315A (en) Antibody therapeutics with local activity in the digestive tract
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
UA108975C2 (uk) Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями
NZ596218A (en) Bssl antagonists for treatment of inflammatory diseases
HUP0800498A2 (en) Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU